Peanut Allergy Market

Market Overview:

The 7 major peanut allergy markets reached a value of USD 476.7 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 1,011.4 Million by 2035, exhibiting a growth rate (CAGR) of 7.08% during 2025-2035.

The peanut allergy market has been comprehensively analyzed in IMARC's new report titled "Peanut Allergy Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Peanut allergy, also known as peanut hypersensitivity, is a food allergy in which the immune system mistakenly identifies peanut proteins as harmful and triggers an allergic reaction. This response occurs within minutes following direct or indirect contact with peanuts. Symptoms of the ailment can range from mild, such as itching and hives, to severe, including anaphylaxis, a life-threatening reaction that can cause difficulty breathing, swelling of the throat, and a drop in blood pressure. Individuals suffering from this illness may also experience digestive problems like stomach cramps, indigestion, diarrhea, nausea, vomiting, etc. The diagnosis of peanut allergy typically involves a combination of physical examination and underlying indications. Additionally, the doctor may investigate the patient's medical history, including a family history of allergies or any known allergies. A blood workup is utilized to monitor the antibodies in the bloodstream against allergies. The healthcare provider may perform certain assessment studies, such as skin prick tests and oral food challenges, to confirm a diagnosis in the patients.

The rising incidences of allergic reactions resulting from an overactive immune system against certain substances or foods are primarily driving the peanut allergy market. In addition to this, the increasing cases of impaired skin barriers due to atopic dermatitis, leading to exposure and penetration of food allergens, are also propelling the market growth. Moreover, the widespread adoption of effective medications, such as epinephrine and antihistamines, to help manage symptoms during an allergic reaction is creating a positive outlook for the market. Apart from this, the escalating utilization of the radioallergosorbent test (RAST) to diagnose the ailment since it aids in identifying the amount of allergen-specific IgE antibodies in the blood is also bolstering the market growth. Furthermore, several key players are making substantial investments in developing novel therapies that target particular pathways to provide more effective relief of indications. This, in turn, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of oral immunotherapy, which is designed to offer durable desensitization to peanuts and reduce the risk of severe reactions, is expected to drive the peanut allergy market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the peanut allergy market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for peanut allergy and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the peanut allergy market in any manner.

Recent Developments:

• In February 2024, Novartis announced that the US FDA had approved Xolair (omalizumab) to reduce allergic reactions, including anaphylaxis, that can occur after accidental exposure to foods in adult and pediatric patients aged one year and older with IgE-mediated food allergy. Xolair is the first and only FDA-approved medication for reducing allergic reactions in patients with one or more food allergies.
• In November 2023, DBV Technologies released positive interim findings from the ongoing Open-Label Extension (OLE) Study of EPITOPE (Phase 3 trial of Viaskin Peanut 250 µg in toddlers ages 1 to 3 years), known as EPOPEX.
• In November 2023, IgGenix, Inc. published new findings as part of an international effort on the involvement of human monoclonal IgE antibodies in peanut allergy. These antibodies and the findings of cutting-edge research provide the basis for the development of allergy-specific therapies.
• In June 2023, Aravax announced that the company had dosed PVX108 to the first patient in a Phase 2 study (AVX-201) for the safe and convenient treatment of peanut allergy. The study is being carried out under a US FDA Investigational New Drug Application.

Key Highlights:

• Peanut allergy affects around one out of every fifty children and one out of every 200 adults.
• The estimated prevalence of peanut allergy among US adults was 1.8%, with more than one in every six persons with peanut allergy having adult-onset allergy.
• Peanut allergy commonly develops in childhood, with symptoms appearing as early as four months of age and frequently within the first two years of life.
• According to certain studies, the severity of peanut-related symptoms increases with age.
• Approximately 20% of children will naturally overcome their peanut allergy and tolerate it without incident later in life.

Drugs:

PALFORZIA is a therapy for peanut allergies. The drug can help minimize the severity of allergic responses, such as anaphylaxis, that might occur after being accidentally exposed to peanuts. PALFORZIA can be begun in patients aged 4 to 17 years old.

CNP-201 is a biodegradable nanoparticle that contains refined peanut protein extract and is delivered by intravenous infusion. Peanut allergen-containing nanoparticles are absorbed by immune-presenting cells. When particles and allergens are introduced within the immune processing cell, they cause reprogramming of the immune system's biological processes, lowering and eliminating the likelihood of severe allergic reactions.

Viaskin Peanut is a revolutionary type of allergy immunotherapy in development. Peanut allergens are delivered via a patch worn on intact skin. To desensitize allergy sufferers to peanuts and prevent future attacks, allergens are administered to stimulate the immune system. The patch is designed for children aged 4-11 who avoid peanuts and are at risk of severe responses if mistakenly exposed to them.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the peanut allergy market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the peanut allergy market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current peanut allergy marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the peanut allergy market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the peanut allergy market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the peanut allergy market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2019-2035​) of peanut allergy across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of peanut allergy by age across the seven major markets?
• What is the number of prevalent cases (​2019-2035​) of peanut allergy by gender across the seven major markets?
• How many patients are diagnosed (​2019-2035​) with peanut allergy across the seven major markets?
• What is the size of the peanut allergy patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of peanut allergy?
• What will be the growth rate of patients across the seven major markets?
   

Peanut Allergy: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for peanut allergy drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the peanut allergy market?
• What are the key regulatory events related to the peanut allergy market?
• What is the structure of clinical trial landscape by status related to the peanut allergy market?
• What is the structure of clinical trial landscape by phase related to the peanut allergy market?
• What is the structure of clinical trial landscape by route of administration related to the peanut allergy market?